trending Market Intelligence /marketintelligence/en/news-insights/trending/PHWY2lh0M5SfpmTsRKGgNA2 content esgSubNav
In This List

Windtree's heart failure drug gets US FDA fast-track status

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Windtree's heart failure drug gets US FDA fast-track status

The U.S. Food and Drug Administration granted fast-track designation to Windtree Therapeutics Inc.'s heart failure drug.

The Warrington, Pa.-based biotechnology company is developing istaroxime to treat symptoms of acute heart failure, a disease characterized by the sudden appearance or abrupt worsening of symptoms of heart failure.

Results from the company's phase 2 study showed that istaroxime improved cardiac function in patients with acute heart failure compared to placebo. The drug also maintained or increased blood pressure and decreased heart rate during the infusion in the mid-stage study.

The U.S. regulator grants fast-track designations to expedite the review of drugs that treat serious conditions and fill unmet medical needs. Incentives include frequent meetings and communications with the FDA and potential accelerated approval, priority review or rolling review.